Navigation Links
Antidepressants for bipolar disorder
Date:12/24/2013

The use of antidepressants in the treatment of bipolar disorder remains controversial. Some studies and treatment guidelines suggest that antidepressant treatment for bipolar disorder may have the potential to increase the manic switch, while others recommend short-term antidepressant treatment and early discontinuation. A recent study by Dr. Yingli Zhang and co-workers from Mental Health Institute of Central South University in China involved new large-sample double-blind randomized controlled trials, excluded open-label design studies, and supplemented studies involving homogeneous patients. Suicidality firstly served as an important outcome, strict inclusion criteria included limitation to double-blind randomized controlled studies and interventional treatment without use of antipsychotics to make the study results more objective and convincing. The results from this study do not support that antidepressants are more effective in the treatment of bipolar disorder. Antidepressants are not superior to placebo and other medication in short-term, and long-term use of antidepressants cannot achieve higher response and remission rates of bipolar disorder. These findings, published in the Neural Regeneration Research (Vol. 8, No. 31, 2013), guide future clinical studies and provide evidence for preparing treatment strategy for bipolar disorder.


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert

Page: 1

Related biology news :

1. mTOR: A key brain signaling mechanism for rapidly acting antidepressants
2. OHSU Vollum Institute research gives new insight into how antidepressants work in the brain
3. Biochemical mapping helps explain who will respond to antidepressants
4. Do antidepressants impair the ability to extinguish fear?
5. What is the brain telling us about the diagnoses of schizophrenia and bipolar disorder?
6. New gene variant may explain psychotic features in bipolar disorder
7. Dartmouth research offers new control strategies for bipolar bark beetles
8. MBL scientists find bipolar marine bacteria, refuting everything is everywhere idea
9. Making sense out of the biological matrix of bipolar disorder
10. Quadriplegics at risk for serious sleep breathing disorder
11. An important discovery related to anxiety disorders and trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: